Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease

Annals of Neurology

Volumn 42, Issue 4, 1997, Pages 613-621

  Schiffmann, Raphael ^a,e   Heyes, Melvyn P ^a   Aerts, J M ^b   Dambrosia, James M ^c   Patterson, Marc C ^a   DeGraba, Thomas ^a   Parker, Colette C ^a   Zirzow, Gregory C ^a   Oliver, Katherine ^a   Tedeschi, Gioacchino ^a   Brady, Roscoe O ^a   Barton, Norman W ^a   Nagineni, Chandra ^d   Kaneski, Christine R ^c   Murray, Gary J ^c   Higgins, Joseph J ^c   Tournay, Anne ^c   Banerjee, Tapas K ^c   Kreps, Constance ^c   Scott, Leland J C ^c   McKee, Mary Ann ^c   Crutchfield, Kevin ^c   Frei, Karen ^c   more..

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^d NATIONAL EYE INSTITUTE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGLUCERASE; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDE; GLYCOSIDASE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NITRITE; PSYCHOSINE; QUINOLINIC ACID; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME REPLACEMENT; FEMALE; GAUCHER DISEASE; HUMAN; MALE; NEUROLOGIC DISEASE; PRECOCIOUS PUBERTY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ANTIBODIES; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; FEMALE; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HEXOSAMINIDASES; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MACROPHAGES; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TESTS; NITRITES; PROSPECTIVE STUDIES; PSYCHOSINE; QUINOLINIC ACID; RECEPTORS, INTERLEUKIN-1; SIALOGLYCOPROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0030772366     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410420412     Document Type: Article

References (45)

1. Brady RO, Kanfer JN, Bradley RM, Shapiro D. Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. J Clin Invest 1966;45:1112-1115
2. Beutler E, Grabowski GA. Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 1995: 2641-2670
3. Zimran A, Gelbart T, Westwood B, et al. High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews. Am J Hum Genet 1991;49:855-859
4. Beutler E, Nguyen NJ, Henneberger MW, et al. Gaucher disease: gene frequencies in the Ashkenazi Jewish population. Am J Hum Genet 1993;52:85-88
5. Winkelman MD, Banker BQ, Victor M, Moser HW. Non-infantile neuronopathic Gaucher's disease: a clinicopathologic study. Neurology 1983;33:994-1008
6. Abrahamov A, Elstein D, Gross-Tsur V, et al. Gaucher's disease variant characterised by progressive calcification of heart valves and unique genotype. Lancet 1995;346:1000-1003 (Comments)
7. Patterson MC, Horowitz M, Abel RB, et al. Isolated horizontal supranuclear gaze palsy as a marker of severe systemic involvement in Gaucher's disease. Neurology 1993;43:1993-1997
8. Kaye EM, Ullman MD, Wilson ER, Barranger JA. Type 2 and type 3 Gaucher disease: a morphological and biochemical study. Ann Neurol 1986;20:223-230
9. Erikson A. Gaucher disease - Norrbottnian type (III). Neuropaediatric and neurobiological aspects of clinical patterns and treatment. Acta Paediatr Scand Suppl 1986;326:1-42
10. Barton NW, Furbish FS, Murray GJ, et al. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci USA 1990;87:1913-1916
11. Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency - macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991;324:1464-1470 (Comments)
12. Ossege LM, Voss B, Wiethege T, et al. Detection of transforming growth factor beta 1 mRNA in cerebrospinal fluid cells of patients with meningitis by non-radioactive in situ hybridization. J Neurol 1994;242:14-19
13. Reinhard JF Jr, Erickson JB, Flanagan EM. Quinolinic acid in neurological disease: opportunities for novel drug discovery. Adv Pharmacol 1994;30:85-127
14. Hollak CE, Van Weely S, van Oers MH, Acrts JM. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 1994;93:1288-1292
15. Kuiper MA, Visser JJ, Bergmans PLM, et al. Decreased cerebrospinal fluid nitrate levels in Parkinson's disease, Alzheimer's and multiple system atrophy patients. J Neurol Sci 1994;121:46-49
16. Rosenthal DI, Barton NW, McKusick KA, et al. Quantitative imaging of Gaucher disease. Radiology 1992;185:841-845
17. Rapoport SI, Pettigrew KD. A heterogenous, pore-vesicle membrane model for protein transfer from blood to cerebrospinal fluid at the choroid plexus. Microvasc Res 1979;18:105-119
18. Broadwell RD, Balin BJ, Salcman M. Transcytotic pathway for blood-borne protein through the blood-brain barrier. Proc Natl Acad Sci USA 1988;85:632-636
19. Broadwell RD. Transcytosis of macromolecules through the blood-brain barrier: a cell biological perspective and critical appraisal. Acta Neuropathol (Berl) 1989;79:117-128
20. Pentchev PG, Kusiak JW, Barranger JA, et al. Factors that influence the uptake and turnover of glucocerebrosidase and α-galactosidase in mammalian liver. In: Gatt S, Freysz L, Mandel P, eds. Enzymes of lipid metabolism. New York: Plenum Press, 1997:745-752
21. Tedeschi G, Schiffmann R, Barton NW, et al. Proton magnetic resonance spectroscopic imaging in childhood ataxia with diffuse central nervous system hypomyelination. Neurology 1995;45:1526-1532
22. Murray GJ, Youle RJ, Gandy SE, et al. Purification of glucocerbrosidase by preparative scale HPLC: the use of ethylene glycol containing buffers for chromatography of hydrophobic glycoprotein enzymes. Anal Biochem 1985;147:301-310
23. Ullman MD, McCluer RH. Quantitative analysis of plasma neutral glycosphingolipids by high performance liquid chromatography of perbenzoyl derivatives. J Lipid Res 1977;18:371-378
24. Green LC, Wagner DA, Glogowski J, et al. Analysis of nitrate, nitrite, an [15N]nitrate in biological fluids. Anal Biochem 1982;126:131-138
25. Saito K, Nowak TS, Markey SP, Heyes MP. Mechanism of delayed increases in kynurenine pathway metabolism in damaged brain regions following transient cerebral ischemia. J Neurochem 1993;60:180-192
26. Boot RG, Renkema GH, Strijland A, et al. Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages. J Biol Chem 1995;270:26252-26256
27. Renkema GH, Boot RG, Muijsers AO, et al. Purification and characterization of human chitotriosidase, a novel member of the chitinase family of proteins. J Biol Chem 1995;270:2198-2202
28. Grabowski GA, Barton NW, Pastores G, et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995;122:33-39
29. Woolson RF. Statistical methods for the analysis of biomedical data. New York: John Wiley, 1987:170-172
30. Brouwers P, Heyes MP, Moss H, et al. Quinolinic acid in cerebrospinal fluid of children with symptomatic human immunodeficiency virus type-1 disease: relationships to clinical status and therapeutic response. J Infect Dis 1993;168:1380-1386
31. Heyes MP, Saito K, Crowley JS, et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 1992;115:1249-1273
32. Renkema GH, Boot RG, Stryland A, et al. Synthesis, sorting, and processing into distinct isoforms of human macrophage chitotriosidase. Eur J Biochem 1997;244:279-285
33. Heyes MP, Saito K, Milstein S, et al. A mechanism of quinolinic acid synthesis by brain in inflammatory neurologic disease: attenuation of formation by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilic acid. Brain 1993;116:1425-1450
34. Kim JP, Choi DW. Quinolinate neurotoxicity in cortical cell culture. Neuroscience 1987;25:423-432
35. Whetsell WO, Schwarcz R. Prolonged exposure to submicromolar concentrations of quinolinic acid causes excitotoxic damage in organotypic cultures of rat corticostriatal system. Neurosci Lett 1989;97:271-275
36. Giulian D, Vaca K, Noonan CA. Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1. Science 1990;250:1593-1596
37. Heyes MP, Morrison PF. Quantitation of local de novo synthesis versus blood contributions to quinolinic acid concentrations in brain and systemic tissues. J Neurochem 1997;68:280-288
38. Conradi NG, Sourander P, Nilsson O, et al. Neuropathology of the Norrbottnian type of Gaucher disease. Morphological and biochemical studies. Acta Neuropathol (Berl) 1984;65:99-109
39. Conradi N, Kyllerman M, Mansson JE, et al. Late-infantile Gaucher disease in a child with myoclonus and bulbar signs: neuropathological and neurochemical findings. Acta Neuropathol (Berl) 1991;82:152-157
40. Conradi NG, Kalimo H, Sourander P. Reactions of vessel walls and brain parenchyma to the accumulation of Gaucher cells in the Norrbottnian type (type III) of Gaucher disease. Acta Neuropathol (Berl) 1988;75:385-390
41. Brady RO, Pentchev PG, Gal AE, et al. Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease. N Engl J Med 1974;291:989-993
42. Pentchev PG, Brady RO, Gal AE, Hibbert SR. Replacement therapy for inherited enzyme deficiency: sustained clearance of accumulated glucocerebroside in Gaucher's disease following infusion of purified glucocerebrosidase. J Mol Med 1975;1:73-78
43. Erikson A, Astrom M, Mansson JE. Enzyme infusion therapy of the Norrbottnian (type 3) Gaucher disease. Neuropediatrics 1995;26:203-207
44. Verderese CL, Graham OC, Holder-McShane CA, et al. Gaucher's disease: a pilot study of the symptomatic responses to enzyme replacement therapy. J Neurosci Nurs 1993;25:296-301
45. Cleveland WS. Graphs in scientific publications. Am Stat 1984;38:261-269